Ironwood Pharmaceuticals (IRWD) officer Ronald Silver reports 35,416-share sale

Rhea-AI Filing Summary

Ironwood Pharmaceuticals officer Ronald Silver reported a planned stock sale. On January 5, 2026, he sold 35,416 shares of Ironwood Class A Common Stock at $4.60 per share in a transaction coded as a sale. The filing states this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Silver, which is designed to allow insiders to sell shares according to a set schedule. After this transaction, he beneficially owned 276,809 shares of Ironwood stock, held directly. A footnote explains that the 35,416 shares sold had been acquired under Ironwood’s employee stock purchase plan on December 31, 2025.

Insider Trade Summary

Net Seller: 35,416 shares ($162,914)

Net Sell 1 txn

Insider Silver Ronald

Role Principal Accounting Officer

Sold 35,416 shs ($163K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	35,416	$4.60	$163K

Holdings After Transaction: Class A Common Stock — 276,809 shares (Direct)

Footnotes (1)

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The reporting person acquired 35,416 shares of Class A Common Stock under the issuer's employee stock purchase plan on December 31, 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/07/2026 - 04:05 PM Learn about SEC filing dates

FAQ

Who is the insider involved in this Ironwood Pharmaceuticals (IRWD) filing?

The filing reports a transaction by Ronald Silver, who is an officer of Ironwood Pharmaceuticals serving as Principal Accounting Officer.

How many Ironwood Pharmaceuticals (IRWD) shares did Ronald Silver sell and at what price?

Ronald Silver sold 35,416 shares of Ironwood Class A Common Stock at a price of $4.60 per share on January 5, 2026.

Was the Ironwood (IRWD) insider sale by Ronald Silver made under a Rule 10b5-1 plan?

Yes. A footnote states that the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Ronald Silver.

How many Ironwood Pharmaceuticals (IRWD) shares does Ronald Silver own after the reported sale?

Following the reported transaction, Ronald Silver beneficially owned 276,809 shares of Ironwood Class A Common Stock, held directly.

Where did the 35,416 Ironwood (IRWD) shares sold by Ronald Silver come from?

A footnote explains that Ronald Silver acquired 35,416 shares of Class A Common Stock under Ironwood’s employee stock purchase plan on December 31, 2025.

What type of security was involved in Ronald Silver’s Ironwood (IRWD) transaction?

The transaction involved non-derivative equity, specifically Ironwood’s Class A Common Stock, reported in Table I of the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silver Ronald

(Last) (First) (Middle)

C/O IRONWOOD PHARMACEUTICALS, INC.

100 SUMMER STREET, SUITE 2300

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/05/2026		S(1)		35,416	D	$4.6	276,809(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The reporting person acquired 35,416 shares of Class A Common Stock under the issuer's employee stock purchase plan on December 31, 2025.

	/s/ Amir Vitale, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.